Cited in:


This article has been cited by:

  1. 1
    E. Galmozzi, M. Viganò, P. Lampertico, Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?, Alimentary Pharmacology & Therapeutics, 2014, 39, 6
  2. 2
    K. Domagalski, M. Pawłowska, A. Zaleśna, M. Tyczyno, M. Skorupa-Kłaput, A. Tretyn, W. Halota, The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection, European Journal of Clinical Microbiology & Infectious Diseases, 2014, 33, 11, 2025


  3. 3
    Mauro Viganò, Giampaolo Mangia, Pietro Lampertico, Results of Treatment of Chronic Hepatitis B with Pegylated Interferon, Clinics in Liver Disease, 2013, 17, 3, 425


  4. You have free access to this content4
    Pietro Lampertico, Mauro Viganò, Massimo Colombo, Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?, Liver International, 2013, 33,